StockTipsArenaBeta

BUY Gland Pharma Limited — Raja Venkatraman

BUYGland Pharma Limited
Gland Pharma share price target & all analyst calls
⏳ Pending entry — level not yet reached

byRaja VenkatramanHorizon: 1–3 months7 Oct 2026via LiveMint Buy-or-Sell (topic)

Entry₹3,010Stated
Target₹3,325
Total upside +10.47%
Stop loss₹2,910-3.32% risk
CMP₹3,079.13h ago
ActiveNA 3 mo left
Follow Raja Venkatraman for new calls(29% target hit, 42 closed calls)Get alertsWatch GLAND for new buy/sell callsGet alertsSee 3 other Short-term calls on GLANDSee 66 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Oct, 7:55 pm IST
6 supporting1 neutral2 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·8 Oct · today

7 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·7 Oct · yesterday

Gland Pharma to invest $21 million in US drugmaker, take 60% stake

NewsCnbc-Tv18·1 Oct · 1w ago

(opens in new tab)

Gland Pharma Ltd acquired Gland Pharma USA Inc., a wholly-owned step-down subsidiary, from Gland Pharma International Pte. Ltd.

BSE · Company Update·13 Sept · 4w ago

(opens in new tab)

Gland Pharma Limited's Board of Directors approved the acquisition of 100% equity share capital of Gland Pharma USA Inc., a step-down subsidiary, to streamline corporate structure. The acquisition is

BSE · Others·13 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (1)

Gland Pharma Limited's Board approved the acquisition of 100% equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. This move aims to streamline the corporate structu

NSE · Outcome of Board Meeting·13 Sept · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

RSI at 72 — overbought territory

Technicals · rsi·8 Oct · today

2 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·12 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Gland Pharma

All analyst calls on Gland Pharma

More from Raja Venkatraman

Every call and its outcome